Faruqi & Faruqi, LLP partner in disputes for securities James (Josh) Wilson Encourages investors who have suffered losses in the cassava to turn directly to him to talk about their capabilities
If you bought or acquired securities in cassava Between February 7, 2024 and November 24, 2024 and want to talk about your legal rights, call Faruqi & Faruqi partner Josh Wilson directly on 877-247-4292 or 212-983-9330 (LOK. 1310).
[You may also click here for additional information]
New York, New York – (Newsfile Corp. – January 25, 2025) – Faruqi & Faruqi, LLP, a leading national legal papers, investigates potential lawsuits against Cassava Sciences (Nasdaq :), Inc. (“Cassava” or “Company”) (Nasdaq: Sava) and reminds investors of 10. February 2025. Deadline seek the role of a leading prosecutor in a federal collective lawsuit against securities that was filed against society.
Faruqi & Faruqi is a leading national legal papers with offices in New York, Pennsylvania, California and Georgia. The company has regained hundreds of millions of dollars for investors since its inception in 1995. See www.faruqilaw.com.
The complaint states that the defendants gave investors significant information about the leading Cassave medicines candidate, Simufilam. The defendant’s statements included, among other things, a clear confidence in the ability of simufiles to treat Alzheimer’s disease. The defendants made these extremely positive statements to investors while, at the same time, they spread materially false and wrong statements and/or concealed material adverse facts regarding the actual capabilities of Cassava’s drugs; Specifically, this company simply did not have a cure that could relieve Alzheimer’s progress. Such statements without these material facts have cited prosecutors and other shareholders to buy Cassavine value papers at artificially inflated prices. On November 25, 2024. Cassava published the results of the first of its two current stages of 3 studies on Simufilam, study “Rothink-Alz”. The results showed that Simufilam failed to satisfy each of the presented primary, secondary and research end points; In short, Simufilam failed to surpass the placebo.
After this news, the price of regular Cassave shares fell dramatically. From a closing market price of $ 26.48 per section on November 22, 2024, Cassave’s share price fell at $ 4.30 per section on November 25, 2024, which is a decline of about 83.76% in the range of only one day .
The prosecutor appointed by the court is an investor with the greatest financial interest in the relief sought by the class, which is adequate and typical of the members of the class that directs and monitors the litigation on behalf of the assumed class. Any member of the assumed class may propose to the court to serve as the prosecutor through a lawyer of his own choice or may decide not to do anything and remain absent a member of the class. Your ability to participate in any refund is not influenced by the decision whether to be the prosecutor or not.
Faruqi & Faruqi, LLP also encourages anyone who has information about Cassave’s behavior to contact the company, including whistleblowers, former employees, shareholders and others.
Follow us for updates on Linkedin, on X or Facebook (Nasdaq :).
Advertising lawyers. The law firm responsible for this ad is Faruqi & Faruqi, LLP (www.faruqilaw.com). Previous results do not guarantee or foresee a similar outcome with respect to any future question. We welcome the opportunity to talk about your specific case. All communication will be treated in a confidential way.
For an overview of the original version of this press release, visit https://www.newsfilecorp.com/release/238340
